Study of F527 in Patients With Relapsed or Refractory Lymphoma

Relapsed/Refractory Lymphoma Clinical Trial

Official title:
Phase I Clinical Study of Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of F527 in the Treatment of Patients With Relapsed or Refractory Lymphoma

Status Not yet recruiting

Clinical Trial Summary

This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients with relapsed or refractory lymphoma sexual characteristics.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05293028
Study type	Interventional
Source	Shandong New Time Pharmaceutical Co., LTD
Contact	Shaohong Yin
Phone	86-15265901803
Email	yinshaohong@lunan.com.cn
Status	Not yet recruiting
Phase	Phase 1
Start date	May 20, 2022
Completion date	May 20, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02259010` - A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma	Phase 1
Recruiting	`NCT05400876` - To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05713110` - A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma	Phase 2
Recruiting	`NCT05189093` - Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma	Phase 1/Phase 2
Terminated	`NCT05271279` - A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors	Early Phase 1
Completed	`NCT02214147` - Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function	Phase 1